InVivoSIM anti-human mesothelin (Amatuximab Biosimilar)

Clone Catalog # Category
Amatuximab SIM0040
USD 224 - USD 7752

About InVivoSIM anti-human mesothelin (Amatuximab Biosimilar)

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Amatuximab, making it ideal for research use. Amatuximab is a high-affinity chimeric monoclonal antibody that reacts with mesothelin (MSLN). Human MSLN is synthesized as a 71-kDa precursor that translocates to the cell surface, where it is cleaved into 31-kDa megakaryocyte potentiating factor (MPF) and 40-kDa mature MSLN protein. MSLN is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein whose expression in adult humans is restricted to mesothelium. Notably, MSLN is found over-expressed in many epithelial cancers, such as epithelial mesotheliomas, ovarian cancers, lung adenocarcinomas, and pancreatic ductal adenocarcinomas. MSLN interacts with cancer antigen 125 (CA125), a specific epitope expressed on MUC16, and it is suggested to play a role in tumorigenesis and metastasis. The tumor-specific expression of MSLN makes it an attractive target antigen for cancer immunotherapy. Amatuximab has been shown to elicit antibody-dependent cellular cytotoxicity (ADCC) against MSLN+ cancer cell lines in vitro, and a greater efficacy in mouse tumor xenografts when combined with chemotherapy.

InVivoSIM anti-human mesothelin (Amatuximab Biosimilar) Specifications

IsotypeHuman IgG1, κ
ImmunogenHuman mesothelin
Reported Applicationsin vivo functional assays in vitro functional assays ELISA Western blot Flow cytometry
FormulationPBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay
Aggregation<5% Determined by SEC
Purity>95% Determined by SDS-PAGE
Sterility0.2 μm filtration
ProductionPurified from cell culture supernatant in an animal-free facility
Molecular Weight150 kDa
StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.